The enzyme mTOR (mammalian target of rapamycin) is selected for ubiquitination and subsequent degradation by binding to the tumour suppressor protein FBXW7

FBXW7 loss and deletion or mutation of PTEN (phosphatase and tensin homolog), which also activates mTOR were reciprocally related in human breast cancer cell lines and primary tumours.
Tumour cell lines with deletions or mutations of FBXW7 inside their genome were observed to be especially sensitive to rapamycin treatment. The loss of FBXW7 could thus be used as a biomarker for human cancers that are treatable with mTOR pathway inhibitors.

Related antibodies on antibodies-online.com:

mTOR

FBXW7

PTEN

Antibodies for the research area enzymes: »Show antibodies

Antibodies for the research area oncology: »Show antibodies